Imipenem/cilastatin/relebactam
| Combination of | |
|---|---|
| Imipenem | β-Lactam antibiotic |
| Cilastatin | Dehydropeptidase inhibitor |
| Relebactam | β-Lactamase inhibitor |
| Clinical data | |
| Trade names | Recarbrio |
| Other names | MK-7655A |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a619046 |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio(Merck),[1] is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections.[3][4][5][6] It is administered via intravenous injection.[7][1]
The most common adverse reactions include nausea, diarrhea, headache, fever and increased liver enzymes.[3]
The most common adverse reactions observed in people treated for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) include increased aspartate/alanine aminotransferases (increased liver enzymes), anemia, diarrhea, hypokalemia (low potassium), and hyponatremia (low sodium).[8]
- ^ a b c "Recarbrio EPAR". European Medicines Agency (EMA). 10 December 2019. Retrieved 1 March 2020.
- ^ "Recarbrio Product information". Union Register of medicinal products. Retrieved 3 March 2023.
- ^ a b "FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections". U.S. Food and Drug Administration (FDA) (Press release). 17 July 2019. Archived from the original on 20 November 2019. Retrieved 20 November 2019. This article incorporates text from this source, which is in the public domain.
- ^ "Drug Trial Snapshot: Recarbrio". U.S. Food and Drug Administration (FDA). 2 August 2019. Archived from the original on 20 November 2019. Retrieved 20 November 2019. This article incorporates text from this source, which is in the public domain.
- ^ "Recarbrio (imipenem, cilastatin, and relebactam) FDA Approval History". Drugs.com. 21 July 2019. Retrieved 20 November 2019.
- ^ "Drug Approval Package: Recarbrio". U.S. Food and Drug Administration (FDA). 22 July 2019. Retrieved 1 March 2020.
- ^ "Recarbrio- imipenem anhydrous, cilastatin, and relebactam anhydrous injection, powder, for solution". DailyMed. 4 December 2019. Retrieved 1 March 2020.
- ^ Cite error: The named reference
FDA PR 20200604was invoked but never defined (see the help page).